This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathing passages to the lung partially or completely blocked. These tumors could be due to lung cancer or other cancers (e.g., renal, breast, kidney, etc.) that spread to the lung. This blockage puts the patient at a higher risk for respiratory failure, post-obstructive pneumonia, and prolonged hospitalizations. Treatment for these patients may include bronchoscopic intervention (such as mechanical removal, stenting, laser cauterization, or ballooning), radiation therapy with and without chemotherapy. While palliative x-ray radiotherapy may help in shrinking the tumor, high dose curative radiotherapy that can ablate (a localized, nonsurgical destruction) the tumor also has high risk to cause significant toxicity, including bleeding, abnormal connections or passageways between organs or vessels and abnormal scar tissue that can also produce airway obstruction. Photodynamic therapy (PDT) is another possible treatment that can provide local control of the tumor. PDT consists of injecting a light sensitive drug (photosensitizer, PS) into the vein, waiting for the PS to accumulate in the tumor, and then activating it with a red laser light. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving interstitial photodynamic therapy following palliative radiotherapy may improve tumor response and survival without the serious side effects that are associated with the typical high dose curative x-ray radiotherapy alone in patients with malignant central airway obstruction.
Additional locations may be listed on ClinicalTrials.gov for NCT06306638.
Locations matching your search criteria
United States
New York
Buffalo
Roswell Park Cancer InstituteStatus: Active
Contact: Nathaniel Ivanick
Phone: 716-845-5873
PRIMARY OBJECTIVES:
I. To test the safety of our image-based treatment planning for image-guided interstitial photodynamic therapy (I PDT) with endobronchial ultrasound (EBUS) following standard of care palliative radiotherapy (p-XRT). (Phase I)
II. To assess the efficacy of our image-based treatment planning for image-guided I-PDT following standard of care p-XRT. (Phase II)
SECONDARY OBJECTIVES:
I. To assess objective tumor response. (Phase I)
II. To evaluate changes in quality of life. (Phase I and II)
III. To measure changes in functional lung capacity. (Phase I and II)
IV. To measure the relationship between the measured objective tumor response (at 12 +/- 2 weeks post I-PDT) and changes in therapeutic laser light transmission within the target tumor, as a future dosimetric marker for response. (Phase I and II)
V. To assess treatment effects on the immune contexture. (Phase I and II)
VII. To monitor progression free survival. (Phase I and II)
EXPLORATORY OBJECTIVE:
I. Assess the relationship between drug levels in the plasma to tumor response.
OUTLINE: This is a phase I study, followed by a phase II.
PHASE I: Patients are assigned to 1 of 2 cohorts.
COHORT 1: Patients receive verteporfin (Visudyne) intravenously (IV) over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after Visudyne for 1 treatment session. 33 to 44 days later, patients undergo standard of care (SOC) p-XRT over a single fraction. Patients receive Visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after Visudyne for 1 treatment session. Patients undergo blood and tissue sample collection on study. Patients also undergo computed tomography (CT) throughout the trial.
COHORT 2: Patients undergo SOC p-XRT over a single fraction. Patients receive Visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after Visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
PHASE II: Patients undergo SOC p-XRT over a single fraction. Patients receive Visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after Visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.
After completion of study treatment, patients are followed up at 30 days and 8, 12, and 24 weeks.
Lead OrganizationRoswell Park Cancer Institute
Principal InvestigatorNathaniel Ivanick
